Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Given a $160.00 Price Target at Piper Sandler

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) has been given a $160.00 price objective by stock analysts at Piper Sandler in a report issued on Monday, Marketbeat.com reports. The brokerage presently has an “overweight” rating on the stock. Piper Sandler’s price target suggests a potential upside of 68.23% from the stock’s current price.

Other analysts have also recently issued research reports about the stock. HC Wainwright raised their target price on shares of Verona Pharma PLC American Depositary Share from $85.00 to $90.00 and gave the stock a “buy” rating in a research note on Monday, June 2nd. Cowen began coverage on shares of Verona Pharma PLC American Depositary Share in a research note on Monday, April 28th. They issued a “buy” rating for the company. Wells Fargo & Company raised their price objective on shares of Verona Pharma PLC American Depositary Share from $107.00 to $138.00 and gave the company an “overweight” rating in a research report on Friday, June 20th. Jefferies Financial Group raised their price objective on shares of Verona Pharma PLC American Depositary Share from $95.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, June 11th. Finally, Cantor Fitzgerald raised their price target on Verona Pharma PLC American Depositary Share from $90.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, June 11th. Eleven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Verona Pharma PLC American Depositary Share currently has an average rating of “Buy” and a consensus target price of $101.10.

Verona Pharma PLC American Depositary Share Price Performance

Shares of VRNA opened at $95.11 on Monday. Verona Pharma PLC American Depositary Share has a fifty-two week low of $14.14 and a fifty-two week high of $99.01. The firm has a 50-day simple moving average of $76.98 and a 200-day simple moving average of $63.25. The company has a debt-to-equity ratio of 1.07, a quick ratio of 8.73 and a current ratio of 8.86. The company has a market capitalization of $8.10 billion, a price-to-earnings ratio of -47.56 and a beta of 0.21.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.49. The company had revenue of $98.65 million for the quarter, compared to analyst estimates of $41.47 million. On average, equities research analysts anticipate that Verona Pharma PLC American Depositary Share will post -1.95 earnings per share for the current year.

Insider Activity

In other Verona Pharma PLC American Depositary Share news, CFO Mark W. Hahn sold 32,432 shares of Verona Pharma PLC American Depositary Share stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $9.53, for a total transaction of $309,076.96. Following the completion of the transaction, the chief financial officer now owns 13,046,560 shares in the company, valued at approximately $124,333,716.80. The trade was a 0.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Vikas Sinha sold 20,000 shares of Verona Pharma PLC American Depositary Share stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $8.92, for a total transaction of $178,400.00. Following the transaction, the director now owns 74,440 shares of the company’s stock, valued at approximately $664,004.80. The trade was a 21.18% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 1,965,800 shares of company stock worth $20,056,881. Company insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC acquired a new position in shares of Verona Pharma PLC American Depositary Share during the 4th quarter worth approximately $720,000. Wells Fargo & Company MN raised its holdings in shares of Verona Pharma PLC American Depositary Share by 27.2% in the fourth quarter. Wells Fargo & Company MN now owns 67,126 shares of the company’s stock worth $3,117,000 after acquiring an additional 14,362 shares during the last quarter. Northern Trust Corp acquired a new position in shares of Verona Pharma PLC American Depositary Share in the fourth quarter worth $362,000. Cetera Investment Advisers raised its stake in Verona Pharma PLC American Depositary Share by 113.4% in the 4th quarter. Cetera Investment Advisers now owns 23,265 shares of the company’s stock valued at $1,080,000 after purchasing an additional 12,362 shares during the last quarter. Finally, New York State Common Retirement Fund acquired a new position in Verona Pharma PLC American Depositary Share in the 4th quarter valued at about $285,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.